CRDF
Cardiff Oncology, Inc. NASDAQ Listed Jul 27, 2004$1.60
After hrs
$1.65
+0.61%
Mkt Cap $109.4M
52w Low $1.48
3.9% of range
52w High $4.56
50d MA $1.75
200d MA $2.18
P/E (TTM)
-2.5x
EV/EBITDA
-3.8x
P/B
2.5x
Debt/Equity
0.0x
ROE
-101.0%
P/FCF
-4.9x
RSI (14)
—
ATR (14)
—
Beta
1.42
50d MA
$1.75
200d MA
$2.18
Avg Volume
754.0K
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
11055 Flintkote Avenue · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | AMC | -0.18 | -0.11 | +38.9% | 1.70 | +3.5% | +12.4% | +15.3% | +14.1% | +14.1% | +11.2% | — |
| Nov 6, 2025 | AMC | -0.20 | -0.17 | +15.0% | 2.25 | -2.7% | -2.7% | -0.9% | +1.8% | -0.4% | -4.4% | — |
| Jul 29, 2025 | AMC | -0.19 | -0.21 | -10.5% | 3.31 | -18.7% | -24.8% | -28.4% | -20.2% | -24.2% | -22.4% | — |
| May 8, 2025 | AMC | -0.19 | -0.20 | -5.3% | 2.63 | +1.1% | +1.1% | +4.6% | +3.4% | +1.5% | +4.6% | — |
| Feb 27, 2025 | AMC | -0.26 | -0.21 | +19.2% | 4.06 | -0.7% | +4.4% | -5.9% | -7.9% | +5.2% | -4.4% | — |
| Nov 7, 2024 | AMC | -0.27 | -0.25 | +7.4% | 4.09 | +1.0% | -24.7% | -15.4% | -23.2% | -27.4% | -30.6% | — |
| Aug 8, 2024 | AMC | -0.25 | -0.26 | -4.0% | 2.13 | +1.4% | +11.7% | +6.1% | +5.6% | +2.3% | +12.2% | — |
| May 2, 2024 | AMC | -0.25 | -0.22 | +12.0% | 4.48 | -11.2% | -21.4% | -22.8% | -26.1% | -28.6% | -24.6% | — |
| Feb 29, 2024 | AMC | -0.26 | -0.21 | +19.2% | 1.77 | +13.0% | +64.4% | +97.2% | +106.2% | +119.8% | +98.3% | — |
| Nov 2, 2023 | AMC | -0.29 | -0.22 | +24.1% | 1.14 | +5.3% | -2.6% | -5.3% | -4.4% | -4.4% | -14.0% | — |
| Aug 9, 2023 | AMC | -0.27 | -0.25 | +7.4% | 1.91 | +9.9% | +8.4% | +3.7% | +4.7% | +4.7% | -1.0% | — |
| May 4, 2023 | AMC | -0.23 | -0.25 | -8.7% | 1.95 | +2.1% | -3.6% | -7.7% | -9.2% | -12.3% | -13.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.70 | $1.76 | +3.5% | +12.4% | +15.3% | +14.1% | +14.1% | +11.2% |
| Jan 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.00 | $2.03 | +1.5% | -19.0% | -19.0% | -12.5% | -14.5% | -16.0% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.57 | $2.50 | -2.7% | -5.1% | -6.2% | -7.0% | -9.3% | -5.4% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.63 | $2.66 | +1.1% | +1.1% | +4.6% | +3.4% | +1.5% | +4.6% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.06 | $4.03 | -0.7% | +4.4% | -5.9% | -7.9% | +5.2% | -4.4% |
| Dec 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $3.27 | $3.60 | +10.1% | +19.9% | +23.2% | +63.6% | +37.3% | +37.3% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.09 | $4.13 | +1.0% | -24.7% | -15.4% | -23.2% | -27.4% | -30.6% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.52 | $3.55 | +0.9% | -1.7% | -6.0% | -9.1% | -4.0% | -3.7% |
| Mar 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.65 | $3.85 | +5.5% | +6.6% | -3.8% | +13.4% | +10.7% | +22.7% |
| Mar 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.77 | $2.00 | +13.0% | +64.4% | +97.2% | +106.2% | +119.8% | +98.3% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.07 | $2.09 | +1.0% | -4.3% | -3.4% | -3.4% | -8.7% | -7.2% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.57 | $1.67 | +6.4% | +38.9% | +21.7% | +31.8% | +26.1% | +27.4% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.80 | $1.79 | -0.6% | -1.7% | -5.0% | -6.1% | -6.1% | -2.8% |
| Mar 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.52 | $1.54 | +1.3% | +8.6% | +8.6% | +8.6% | +5.9% | +0.7% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.72 | $1.75 | +1.7% | +7.6% | +18.0% | +4.7% | +0.6% | -0.6% |
| Sep 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.67 | $1.65 | -1.2% | -5.4% | +3.6% | +3.6% | +3.0% | -1.8% |
| Sep 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $3.21 | $2.50 | -22.1% | -41.1% | -49.5% | -48.0% | -50.8% | -46.1% |
| Aug 29 | Baird | Maintains | Outperform → Outperform | — | $2.62 | $2.52 | -3.8% | -5.7% | -8.0% | +2.7% | +8.4% | +7.3% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.32 | $1.29 | -2.3% | -6.1% | -4.5% | -11.4% | -7.6% | +1.5% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.87 | $2.78 | -3.1% | -6.3% | -6.3% | -11.1% | -16.7% | -18.1% |
| Dec 8 | Baird | Maintains | Outperform → Outperform | — | $5.51 | $5.80 | +5.3% | +11.1% | +4.9% | +2.0% | +2.7% | -2.9% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.78 | $5.94 | +2.8% | +3.5% | +2.1% | +2.2% | -0.7% | -5.5% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.49 | $9.48 | -0.1% | -4.0% | -8.1% | -10.4% | -10.5% | -9.9% |
| Oct 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.02 | $12.50 | +4.0% | +11.5% | +18.4% | +19.4% | +25.7% | +21.5% |
| Oct 8 | Piper Sandler | Maintains | Overweight → Overweight | — | $13.51 | $14.14 | +4.7% | +28.1% | +27.7% | +22.4% | +15.3% | +15.2% |
| Sep 18 | Maxim Group | Maintains | Buy → Buy | — | $8.11 | $8.47 | +4.4% | +7.4% | +43.0% | +44.4% | +40.0% | +32.1% |
| Mar 8 | Noble Financial | Maintains | Outperform → Outperform | — | $4.13 | $8.90 | +115.5% | +16.2% | +17.4% | +7.5% | +3.9% | -6.3% |
| Jun 15 | Maxim Group | Upgrade | Hold → Buy | — | $5.04 | $5.10 | +1.2% | -3.6% | -2.4% | -1.2% | +1.2% | -2.4% |
| Nov 10 | Maxim Group | Downgrade | Buy → Hold | — | $48.96 | $50.40 | +2.9% | -1.5% | +0.0% | -4.4% | -8.8% | -10.3% |
| Mar 16 | PiperJaffray | Downgrade | Neutral → Underweight | — | $126.00 | $100.80 | -20.0% | -25.7% | -25.7% | -32.6% | -38.3% | -42.9% |
| Aug 8 | Cantor Fitzgerald | Upgrade | Hold → Buy | — | $374.40 | $389.52 | +4.0% | +4.6% | +6.7% | +4.0% | +7.1% | +7.9% |
| Apr 26 | Leerink Swann | Downgrade | Outperform → Perform | — | $340.56 | $354.96 | +4.2% | -8.2% | -6.1% | -12.1% | -15.0% | -15.6% |
| Apr 26 | Cantor Fitzgerald | Downgrade | Buy → Hold | — | $340.56 | $354.96 | +4.2% | -8.2% | -6.1% | -12.1% | -15.0% | -15.6% |
| Apr 25 | Cantor Fitzgerald | Downgrade | Buy → Hold | — | $447.12 | $401.76 | -10.1% | -23.8% | -30.1% | -28.5% | -33.0% | -35.3% |
| Apr 25 | PiperJaffray | Downgrade | Overweight → Neutral | — | $447.12 | $401.76 | -10.1% | -23.8% | -30.1% | -28.5% | -33.0% | -35.3% |
| Mar 29 | Avondale Partners | Maintains | Market Perform → Perform | — | $367.92 | $301.68 | -18.0% | -2.0% | -7.4% | -9.0% | -5.9% | -7.2% |
| Mar 11 | Janney Capital | Downgrade | Buy → Neutral | — | $435.60 | $396.72 | -8.9% | -10.7% | -4.0% | -15.0% | -15.0% | -15.5% |
| Jan 6 | Avondale Partners | Maintains | Market Perform → Perform | — | $373.68 | $367.20 | -1.7% | -2.5% | -10.0% | -9.4% | -22.9% | -29.5% |
| Sep 15 | Cantor Fitzgerald | Maintains | Buy → Buy | — | $449.28 | $446.40 | -0.6% | +4.0% | +3.0% | +6.6% | +16.8% | +15.5% |
| Aug 14 | Leerink Swann | Maintains | Outperform → Outperform | — | $436.32 | $453.60 | +4.0% | +0.7% | +7.1% | +0.2% | -5.0% | -10.9% |
| Apr 2 | Janney Capital | Maintains | Buy → Buy | — | $486.00 | $504.00 | +3.7% | +4.4% | +4.7% | +6.7% | +5.9% | +4.4% |
| Feb 17 | PiperJaffray | Maintains | Overweight → Overweight | — | $359.28 | $369.36 | +2.8% | +8.0% | +1.2% | -0.2% | +0.4% | -1.2% |
| Jul 9 | Maxim Group | Maintains | Buy → Buy | — | $241.20 | $241.20 | +0.0% | +1.8% | +0.0% | +2.7% | +2.1% | +2.1% |
| Nov 15 | Aegis Capital | Maintains | Buy → Buy | — | $396.00 | $385.20 | -2.7% | +13.6% | +7.6% | +4.9% | +2.7% | +0.2% |
| Nov 13 | Aegis Capital | Maintains | Buy → Buy | — | $408.96 | $406.08 | -0.7% | -1.9% | -3.2% | +10.0% | +4.2% | +1.6% |
| Jul 16 | Cantor Fitzgerald | Maintains | Buy → Buy | — | $494.64 | $518.40 | +4.8% | +5.7% | +2.6% | +1.7% | +2.5% | +24.3% |
| Dec 20 | Roth Capital | Maintains | Buy → Buy | — | $497.52 | $509.76 | +2.5% | +7.2% | +5.4% | +2.0% | -0.4% | +1.6% |
| Dec 12 | Aegis Capital | Maintains | Buy → Buy | — | $331.92 | $341.28 | +2.8% | +6.3% | +24.3% | +36.0% | +30.8% | +34.5% |
No insider trades available.
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
CRDF appointed Ajay Aggarwal as CFO, signaling potential strategic shifts in financial management that investors should monitor for impacts on operational efficiency and capital allocation decisions.
Apr 9
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
The departure of a director or principal officer at Credify (CRDF) creates uncertainty around leadership continuity and strategic direction, potentially pressuring the stock until management clarity emerges.
Apr 2
8-K · 7.01
! Medium
Cardiff Oncology, Inc. -- 8-K 7.01: Regulation FD Disclosure
Cardiff Oncology is preparing investor presentation materials for upcoming third-party meetings, signaling potential partnership or financing discussions that could impact shareholder value.
Feb 25
8-K
Cardiff Oncology, Inc. -- 8-K Filing
Cardiff Oncology (CRDF) reports strong clinical progress for onvansertib in RAS-mutated colorectal cancer, positioning the company to advance its lead PLK1 inhibitor program into 2026.
Feb 24
Data updated apr 25, 2026 3:07am
· Source: massive.com